This test reveals genetic predispositions to obesity and metabolic dysfunction across all age groups, enabling providers to choose between semaglutide, tirzepatide, or dual-compound GLP-Squared therapy based on a patient's unique peptide-pathway profile rather than age alone
Compounded semaglutide is not FDA-approved and carries quality and safety risks
Once reconstituted, BPC-157 should not remain at room temperature for more than 1-2 hours during use
Weight-Loss Program Our board-certified providers can help with a weight -loss program that includes personalized coaching, Nutritional guidance and weight-loss medication including FDA* approved GLP-1s when appropriate.* Physicals MinuteClinic providers can perform DOT, camp, and Sports physicals
The review traced the developmental history of GLP-1 research from the identification of the proglucagon gene in 1982 through to the contemporary landscape of GLP-1-based therapeutics across obesity, cardiovascular disease, NAFLD, neurodegeneration, and cancer biology